17 July 2013 | News | By BioSpectrum Bureau
The company will manufacture natural astaxanthin, a microalgae-based food supplement with anti-inflammatory properties
Singapore: Fuji Chemical Industry from Japan is planning to set up a $30 million manufacturing unit under its subsidiary AstaReal Technologies.
The biotech plant will manufacture an algae-based product and will hire up to 45 employees and begin operations in late 2014.
Under its subsidiary AstaReal Technologies, the company will manufacture natural astaxanthin, a microalgae-based food supplement with anti-inflammatory properties.
Fuji CEO, Mr Mitsunori Nishida, has said that the company decided to build in Moses Lake because of its cheap hydro power, abundant water, a skilled labor force and local culture welcoming to Japanese companies.